Nachrichten zur Eli Lilly & Co. Aktie

LLY Gets EU Approval for Alzheimers Drug & FDA Nod to Cancer Therapy

Eli Lilly secures EU approval for Alzheimers drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.…

Eli Lilly: Buying The Dip With Confidence

…

Stock Movers: Eli Lilly, CarMax, Jabil

Bloomberg journalists discuss todays biggest winners and losers in the stock market. Listen for analysis on the companies making news…

LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?

Eli Lillys diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity…

Eli Lilly (LLY) Falls More Steeply Than Broader Market: What Investors Need to Know

In the closing of the recent trading day, Eli Lilly (LLY) stood at $746.98, denoting a -1.06% move from the…

Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs

More production capacity for the obesity pill is crucial as Eli Lilly races to bring it to market and tries…

Celltrion unit pays $330 million for Eli Lilly production facility, filing shows

Celltrion Inc. said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC…

Top Analyst Reports for Apple, Eli Lilly & Chevron

Apple grows Services with over 1B subscribers, while Eli Lilly and Chevron face mixed industry and market dynamics.…

Eli Lilly: Orforglipron Sets Path Of Continued Revenue Growth In T2D And Obesity

…

Exclusive: Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts

Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according…

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment…

Heres Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today @themotleyfool #stocks $NVO $LLY

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling…

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment…

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny On Weight-Loss ETFs - Hims & Hers Health (NYSE:HIMS)

The FDAs warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss…

LLYs Orforglipron Tops NVOs Oral Pill in Diabetes Study: Whats Next?

Eli Lillys orforglipron beat NVOs Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.…

ANALYSE-FLASH: Berenberg senkt Eli Lilly auf 'Hold' - Ziel runter auf 830 Dollar

HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat Eli Lilly von "Buy" auf "Hold" abgestuft…

Eli Lilly: Starker Kursanstieg nach ATTAIN-2-Ergebnissen

Die Aktie von Eli Lilly (NYSE: LLY) legte am Dienstag deutlich zu und gewann im Tagesverlauf bis zu 5,9 %. Auslöser war die…

Eli Lillys Abnehmpille bleibt trotz enttäuschender Daten ein ernstzunehmender Rivale für Novus orales Wegovy

Nach der Veröffentlichung enttäuschender Studiendaten erholt sich die Aktie von Eli Lilly langsam wieder. Die neue Abnehmpille Orforglipron von Eli…

S&P 500 eases with Eli Lilly; Nasdaq manages record closing high

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight…

Earnings live: Eli Lilly stock slides, Pinterest sells off, Expedia and Block gain after hours

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive…

Dow, S&P 500 end lower; Eli Lilly shares fall after drug data

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight…

Eli Lillys Experimental Weight-Loss Pill Data Disappoints

A new, late-stage clinical study shows disappointing results for Eli Lillys weight loss pill Orforglipron. The experimental drug has less…

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down

Shares of rival Novo Nordisk rose as both companies develop weight loss pills.…

Stocks making the biggest moves midday: Firefly Aerospace, Fortinet, Duolingo, Eli Lilly and more

Here are some of the stocks posting the biggest moves in midday trading.…

Stocks making the biggest moves midday: Fortinet, Duolingo, Eli Lilly, AppLovin and more

Here are some of the stocks posting the biggest moves in midday trading.…

Drugmakers racing to launch the first weight-loss pill

Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to…

Stocks making the biggest moves premarket: Eli Lilly, Peloton, Intel, Duolingo and more

These are the stocks posting the largest moves in premarket trading.…

Eli Lilly shares drop after obesity pill shows modest late-stage trial results

Eli Lillys pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for…

Market movers: Duolingo, Eli Lilly, Warner Bros, Crocs...

…

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight…

Eli Lilly: Neue Abnehmpille zeigt deutliche Wirkung – aber nicht ganz wie erhofft!

Eli Lilly hat neue Studienergebnisse zum oralen GLP?1-Kandidaten Orforglipron vorgelegt. In einer Phase?III-Studie verloren übergewichtige Teilnehmer ohne Diabetes innerhalb von…

Stock Market Today: Dow Futures Rise On Trump Tariff News; Eli Lilly Plunges On Weight-Loss Drug Trial (Live Coverage)

Stock Market Today: The Dow Jones Index rose Thursday on Trump tariff news. Eli Lilly plunged on disappointing weight-loss drug…

Novo Nordisk shares jump as Eli Lillys weight-loss pill data disappoints

Shares in Novo Nordisk rose 13.6% on Thursday after trial data from Eli Lillys experimental weight-loss pill fell short of…

Novo Nordisk shares jump as Eli Lilly obesity pill disappoints By Investing.com

Novo Nordisk shares jump as Eli Lilly obesity pill disappoints…

Lilly raises full-year earnings forecasts on surging demand for weight-loss drug

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug,…

Eli Lilly raises full-year profit forecast on weight-loss drug strength

Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as…

Eli Lilly bricht ein, Novo Nordisk mit Mega-Rebound – das ist der Grund

Paukenschlag im Adipositas-Markt: Das US-amerikanische Pharma-Unternehmen Eli Lilly hat neben den erwarteten Zahlen zum zweiten Quartal frische Studiendaten zur Abnehm-Pille…

Eli Lilly falls after late-stage trial data for oral weight loss therapy

…

Eli Lilly shares tumble on disappointing weight loss drug trial data

Eli Lilly and Co (NYSE:LLY) shares fell more than 10% at the market open as disappointing late-stage trial data for…

Stock Market Today: Dow, S&P 500, Nasdaq Set to Open Up; Trump Tariffs Kick In; Apple, Eli Lilly, Nvidia, AMD, More Movers

Dow, S&P 500, and Nasdaq futures are rising in premarket trading as the stock market digests President Donald Trumps reciprocal…

These 2 stocks are still on our shopping list, and what Eli Lilly needs to deliver on earnings

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Amgen Stock Sinks As Market Eyes MariTides Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after…

Eli Lilly earnings are coming Thursday. Heres what top analysts expect

Wall Street is optimistic heading into Eli Lillys second-quarter earnings report.…

Wegovy maker Novo Nordisk warns on continued copycat-drug challenge as new CEO readied

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy obesity drug,…

Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: Whats Going On? - Hims & Hers Health (NYSE:HIMS), Eli Lilly (NYSE:LLY)

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue…

dpa-AFX ProFeed